Effectiveness of Original Monovalent and Bivalent COVID‐19 Vaccines Against COVID‐19‐Associated Hospitalization and Severe In‐Hospital Outcomes Among Adults in the United States, September 2022–August 2023
DeCuir J, Surie D, Zhu Y, Lauring A, Gaglani M, McNeal T, Ghamande S, Peltan I, Brown S, Ginde A, Steinwand A, Mohr N, Gibbs K, Hager D, Ali H, Frosch A, Gong M, Mohamed A, Johnson N, Srinivasan V, Steingrub J, Khan A, Busse L, Duggal A, Wilson J, Qadir N, Chang S, Mallow C, Kwon J, Exline M, Shapiro N, Columbus C, Vaughn I, Ramesh M, Safdar B, Mosier J, Casey J, Talbot H, Rice T, Halasa N, Chappell J, Grijalva C, Baughman A, Womack K, Rhoads J, Swan S, Johnson C, Lewis N, Ellington S, Dawood F, McMorrow M, Self W, Network F. Effectiveness of Original Monovalent and Bivalent COVID‐19 Vaccines Against COVID‐19‐Associated Hospitalization and Severe In‐Hospital Outcomes Among Adults in the United States, September 2022–August 2023. Influenza And Other Respiratory Viruses 2024, 18: e70027. PMID: 39496339, PMCID: PMC11534416, DOI: 10.1111/irv.70027.Peer-Reviewed Original ResearchConceptsCOVID-19-associated hospitalizationIn-hospital outcomesVaccine effectivenessMonovalent dosesAbsolute VETest-negative case-control designInvasive mechanical ventilationCOVID-19 vaccineMultivariate logistic regressionSevere COVID-19Case patientsCase-control designControl patientsMechanical ventilationUnvaccinated patientsPatientsMonovalent vaccineCOVID-19-like illnessDoseCOVID-19 vaccine effectivenessBivalent vaccineLogistic regressionAdmission dateVaccineHospitalInterim Estimates of 2023–24 Seasonal Influenza Vaccine Effectiveness — United States
Frutos A, Price A, Harker E, Reeves E, Ahmad H, Murugan V, Martin E, House S, Saade E, Zimmerman R, Gaglani M, Wernli K, Walter E, Michaels M, Staat M, Weinberg G, Selvarangan R, Boom J, Klein E, Halasa N, Ginde A, Gibbs K, Zhu Y, Self W, Tartof S, Klein N, Dascomb K, DeSilva M, Weber Z, Yang D, Ball S, Surie D, DeCuir J, Dawood F, Moline H, Toepfer A, Clopper B, Link-Gelles R, Payne A, Chung J, Flannery B, Lewis N, Olson S, Adams K, Tenforde M, Garg S, Grohskopf L, Reed C, Ellington S, Collaborators C, Collaborators C, Lauring A, Arndorfer J, Bride D, Peltan I, Mohr N, Hager D, Prekker M, Mohamed A, Johnson N, Steingrub J, Khan A, Busse L, Duggal A, Wilson J, Qadir N, Mallow C, Kwon J, Exline M, Shapiro N, Columbus C, Vaughan I, Mosier J, Safdar B, Harris E, Chappell J, Stewart L, Swan S, Piedra P, Sahni L, Englund J, Zerr D, Hickey R, Williams J, Rohlfs C, Schlaudecker E, Dosdos D, Moffatt M, Schuster J, Weltmer K, Szilagyi P, Curley T, Mills J, Faryar K, Salata R, Geffel K, Nowalk M, Murthy K, Rose S, Smith M, Wickersham B, Williamson B, Bontrager N, Williams O, Kramer J, Nordstrom L, Monto A, Vaughn I, Dickerson M, McLean C, Noble E, Ray C, Sumner K, Essien I, Fletcher L, Heaton P, Kane S, McEvoy C, Thapa S, Vazquez-Benitez G, Bezi C, Contreras R, Davis G, Lewin B, Mahale P, Patrick R, Qian L, Rayens E, Reyes I, Ryan D, Salas S, Sy L, Yeh M, Zeng X, Fireman B, Goddard K, Hansen J, Jacobson K, Timbol J, Zerbo O, Dunne M, Zhuang Y. Interim Estimates of 2023–24 Seasonal Influenza Vaccine Effectiveness — United States. MMWR Morbidity And Mortality Weekly Report 2024, 73: 168-174. PMID: 38421935, PMCID: PMC10907036, DOI: 10.15585/mmwr.mm7308a3.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultCase-Control StudiesChildHumansInfluenza VaccinesInfluenza, HumanSeasonsVaccine EfficacyConceptsVaccine effectivenessInfluenza vaccineInfluenza virus infectionInfluenza-associated hospitalizationsAnnual influenza vaccinationSeasonal influenza vaccineTest-negative case-control study designCase-control study designOutpatient visitsInfluenza VEInfluenza BInfluenza seasonInfluenza APediatric patientsInfluenzaVirus infectionOutpatient settingMonthsVaccinePatientsStudy designHospitalAdultsVisitsUnited States